About This Project

About the Client: Plexxikon was founded in 2001 by a team of biotech visionaries Joseph Schlessinger, Sung-Hou Kim, K. Peter Hirth, and Thomas R. Kassberg, with the goal of accelerating drug discovery with high throughput crystallography. By focusing on genetic mutations that drive disease proliferation, Plexxikon has earned a reputation as a leader in targeted drug discovery and translational, personalized medicine.  Daiichi Sankyo, a Japanese pharmaceutical company, acquired Plexxikon for $935M back in 2011.

About the Project: This project includes the retrofit of an existing lab space on 2 floors at 329 Oyster Point in South San Francisco.  The previous tenant, Intrexxon/Kiverdi is currently going through the equipment and materials left in the space to determine what will be removed or can be used by Plexxikon.  This project is in the early stages (draft test-fit level) and one of the biggest challenges is determining what needs to be bought to satisfy Plexxikon’s needs for lab equipment.  Additionally, this project is extremely fast-paced, due to Plexxicon’s need to move because their lease in Berkeley is expiring in July 2021. The space will be used primarily as lab space with fume hoods, cold rooms, etc., with office area adjacent, including conference rooms and break rooms.

Nova Partners was hired as the construction project manager and was responsible for complete construction management, including preconstruction services, coordination of the bidding process, and managing the project schedule and budget to a successful completion.


Architect: DGA

General Contractor: Truebeck Construction

Project Size: 55,602 sf

Life Sciences, Specialty